Elanco Animal Health Inc. — Q3 2022 Form 10-Q
Reporting period: Three and nine months ended September 30, 2022. Elanco is a global animal-health company selling products for pets and farm animals in more than 90 countries; it reports as one operating segment. Financial amounts below are in U.S. dollars.
Financial performance
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $1,028 million | $1,131 million | $3,430 million | $3,652 million |
| Net loss | $49 million | $104 million | $23 million | $375 million |
| Loss per diluted share | $0.10 | $0.21 | $0.05 | $0.77 |
| Operating cash flow | Not separately provided for the quarter | Not separately provided for the quarter | $439 million | $260 million |
- Q3 revenue declined 9% reported and 4% at constant exchange rates (CER). Pet Health revenue fell 11% reported (7% CER) to $471 million; Farm Animal fell 7% reported and was flat at CER at $545 million.
- For the first nine months, revenue fell 6% reported and 2% CER. Pet Health declined 7% reported (4% CER) to $1,722 million; Farm Animal declined 4% reported but grew 1% at CER to $1,667 million.
- Q3 cost of sales was 46% of revenue versus 44% a year earlier, implying gross margin of approximately 54% versus 56%. Management cited inflation in inputs, freight and conversion costs and unfavorable mix, partly offset by price increases and manufacturing productivity.
- Nine-month cost of sales was 43% of revenue versus 44%; management said the prior-year comparison included $64 million of acquisition-related inventory fair-value amortization.
- Q3 operating expenses included $26 million of asset impairment, restructuring and other special charges, down from $111 million. Nine-month charges were $158 million, versus $518 million. Interest expense was $60 million for Q3 and $179 million for nine months.
- Nine-month operating cash flow included $207 million of cash proceeds from interest-rate-swap settlements. Investing cash outflow was $103 million; financing cash outflow was $465 million. Cash declined $178 million from year-end 2021 to $460 million.
Financial position and material changes
- At September 30, 2022, total debt carrying value was $5.901 billion, including $394 million current and $5.507 billion long-term; cash and equivalents were $460 million. Debt was $6.319 billion at December 31, 2021. The company reported compliance with all debt covenants.
- During 2022, Elanco issued incremental term facilities and used proceeds primarily to repay revolving-credit borrowings; it also retired $406 million of 4.272% notes due 2023 and repaid $75 million of Term Loan B principal and accrued interest. These repayments generated $19 million of debt-extinguishment losses during the nine months.
- Total assets were $14.948 billion, down from $16.483 billion at year-end 2021. Goodwill was $5.716 billion and other intangibles were $4.766 billion. A Q3 quantitative goodwill test found estimated fair value exceeded carrying value by more than 20%; no impairment was recorded.
- Foreign-currency movements reduced Q3 revenue by 5% and nine-month revenue by 4%. Foreign-currency translation contributed a $973 million loss in other comprehensive income for the nine-month period.
- Q3 net loss improved year over year amid lower special charges and lower operating expenses, despite weaker revenue. The nine-month comparison also benefited from substantially lower prior-year impairment, asset write-down and acquisition-related charges.
Outlook, risks and unusual items
- The filing provides no specific forward revenue or earnings guidance. Management stated that available cash, operating cash flow and credit facilities were expected to be sufficient for planned and existing requirements, and that it expected to remain compliant with debt covenants.
- Management highlighted macroeconomic uncertainty, inflation, supply-chain disruption, raw-material and labor constraints, elevated freight costs, and the Russia-Ukraine conflict. These factors may pressure costs, demand, earnings, cash flow and financing access. COVID-19-related effects and customer or distributor destocking also remain uncertain.
- Q3 Pet Health weakness was linked particularly to parasiticide demand in Europe and the U.S. retail channel, macroeconomic conditions and competition. Farm Animal results reflected cattle-vaccine supply constraints and weaker international swine demand, partly offset by poultry and aqua demand.
- Elanco recorded a $59 million charge for acquired/licensed BexCaFe in-process research and development after determining the asset had no alternative future use. It also recorded $28 million of Speke site write-down charges during the nine months.
- Legal and regulatory matters include Seresto-related consumer lawsuits and EPA petition activity, a Tevra antitrust lawsuit, shareholder litigation, and an SEC subpoena concerning pre-mid-2020 channel inventory and sales practices. The company said no material litigation liabilities were established because no significant claims were both probable and estimable; outcomes remain uncertain.
- A new Indianapolis headquarters lease is expected to commence in 2025, with estimated minimum payments of approximately $378 million over 25 years, excluding extensions. Final payments may vary with construction costs.
- Other risk factors include competition and generics, product safety and regulatory outcomes, reliance on key products, foreign exchange and interest rates, acquisition integration, and substantial indebtedness. Management cautioned that goodwill could be exposed to future impairment if assumptions or market conditions change.
Important facts for investors to verify
- Whether declining parasiticide volumes and channel destocking stabilize, and how much future revenue is affected by foreign exchange versus underlying demand.
- Whether pricing and productivity can offset inflation, freight, labor and supply-chain pressures without further margin deterioration.
- Debt repayment capacity, variable-rate exposure, upcoming maturities and the effect of higher interest rates; confirm covenant compliance in later filings.
- The cash-flow contribution from swap settlements versus recurring operating cash generation, and future working-capital needs.
- Developments in Seresto-related litigation and regulatory review, shareholder suits, and the SEC inquiry, including any material change in estimated exposure.
- Progress and economics of the BexCaFe program, the headquarters commitment, and future goodwill impairment assumptions.